SEHK:1208
SEHK:1208Metals and Mining

A Look At MMG (SEHK:1208) Valuation After The Major Khoemacau Copper Mine Expansion Approval

MMG (SEHK:1208) has moved ahead with a major expansion of its Khoemacau Copper Mine in Botswana, committing about US$900 million to increase output capacity and target lower operating costs. See our latest analysis for MMG. That expansion decision comes after a strong run in the stock, with a 30 day share price return of 11.71% and a 90 day share price return of 31.69%, alongside a very large 1 year total shareholder return that points to momentum still building rather than fading. If MMG’s...
SEHK:6855
SEHK:6855Biotechs

A Look At Ascentage Pharma Group International's Valuation After FDA IND Clearance For APG-3288

Ascentage Pharma Group International (SEHK:6855) has drawn fresh attention after announcing that its BTK-targeted protein degrader APG-3288 received U.S. FDA IND clearance, allowing a global Phase I trial in relapsed or refractory B-cell malignancies. See our latest analysis for Ascentage Pharma Group International. The FDA IND clearance for APG-3288 comes as Ascentage Pharma’s share price sits at HK$54.95, with a 1-day share price return of 1.20% and a 7-day share price return of 7.96%,...
SEHK:3692
SEHK:3692Pharmaceuticals

Hansoh Pharmaceutical Group SEHK 3692 Valuation Check After Ameile First Line Lung Cancer Approval

Hansoh Pharmaceutical Group (SEHK:3692) has just received Chinese NMPA approval to expand lung cancer drug Ameile’s use as a first line option in combination therapy for specific EGFR mutated NSCLC patients. See our latest analysis for Hansoh Pharmaceutical Group. The Ameile update comes after a reshuffle of Hansoh Pharmaceutical Group’s board and committees in late December 2025. The latest 1-day share price return of 2.11% at HK$41.6 sits within a year-to-date share price return of 14.16%...
SEHK:1177
SEHK:1177Pharmaceuticals

Assessing Sino Biopharmaceutical (SEHK:1177) Valuation After Fresh IPF And Psoriasis Trial Milestones

Sino Biopharmaceutical (SEHK:1177) has just reported two key clinical milestones, including first patient enrollment in a Phase III trial for IPF drug candidate TDI01 and positive Phase II data for psoriasis treatment TQH3906. See our latest analysis for Sino Biopharmaceutical. The latest clinical updates arrive after a mixed year for Sino Biopharmaceutical’s shares. The stock has a 7.39% year-to-date share price return at HK$6.83, a 12.44% decline over 90 days, and a very large 1-year total...
SEHK:2419
SEHK:2419Food

A Look At Dekon Food And Agriculture Group (SEHK:2419) Valuation After Its Latest Hog Sales And Pricing Update

Why Dekon Food and Agriculture Group’s Latest Sales Update Matters Dekon Food and Agriculture Group (SEHK:2419) has drawn attention after reporting unaudited December 2025 sales, including 1,109.68 thousand heads of pigs sold and RMB1,663.89 million in revenue, alongside a month on month increase in average hog prices. See our latest analysis for Dekon Food and Agriculture Group. Investors appear to be weighing Dekon Food and Agriculture Group’s strong December sales update against recent...
SEHK:8
SEHK:8Telecom

How Investors Are Reacting To PCCW (SEHK:8) Expanding Its FWD Branding And Marketing Partnership

In December 2025, PCCW Interactive Media Holdings Limited, a subsidiary of PCCW, entered into a Branding and Marketing Arrangements Framework Agreement with FWD Life Insurance covering 1 January 2026 to 31 December 2028, under which PCCW Group (including the HKT Group) will provide branding, spokesperson and marketing services charged at market-referenced rates. The agreement is grounded in arm’s length annual caps informed by historical IFRS-recognised service revenues of about US$6.60...
SEHK:27
SEHK:27Hospitality

Is Galaxy Entertainment’s Broad Staff Bonus Reshaping Its Human Capital Edge in Macau (SEHK:27)?

Galaxy Entertainment Group has announced it will pay a discretionary bonus equivalent to one month of salary to eligible employees on 9 February 2026, covering around 97% of its workforce at senior manager grade or below ahead of the Chinese New Year holiday. This move, the first such bonus announcement among Macau’s six gaming concessionaires for work completed in 2025, highlights management’s focus on staff morale and retention in a highly competitive labour market. We’ll now examine how...
SEHK:1405
SEHK:1405Hospitality

A Look At DPC Dash (SEHK:1405) Valuation After Hitting Store Expansion And Loyalty Milestones

DPC Dash (SEHK:1405), the exclusive Domino’s Pizza franchisee in China, hit its full year store opening target with 1,315 outlets across 60 cities and loyalty membership reaching 35.6 million, highlighting recent operational momentum. See our latest analysis for DPC Dash. Despite the recent operational progress, the share price has been under pressure, with a 30 day share price return of an 8.43% decline and a 90 day share price return of an 18.92% decline, while the 1 year total shareholder...
SEHK:1810
SEHK:1810Tech

Xiaomi (SEHK:1810) Valuation Check After Share Buyback And Fresh Large Cap Growth Endorsement

Investor focus has sharpened on Xiaomi (SEHK:1810) after the company repurchased 3.9 million Type B shares on January 6, 2026, together with fresh attention from a major global investment bank. See our latest analysis for Xiaomi. The recent buyback comes after a tough few months for the share price, with a 90 day share price return of a 27.34% decline and a 30 day share price return of a 9.48% decline. However, the 3 year total shareholder return of 216.22% and 1 year total shareholder return...